Publicaciones (138) Publicaciones de SALVADOR FRANCISC ALIÑO PELLICER

2024

  1. Developments in pharmacogenetics, pharmacogenomics, and personalized medicine

    Pharmacological Research, Vol. 200

  2. Safe Procedure for Efficient Hydrodynamic Gene Transfer to Isolated Porcine Liver in Transplantation

    International Journal of Molecular Sciences, Vol. 25, Núm. 3

2023

  1. Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals

    Frontiers in Allergy

  2. Personalized Medicine in Infant Population with Cancer: Pharmacogenetic Pilot Study of Polymorphisms Related to Toxicity and Response to Chemotherapy

    Cancers, Vol. 15, Núm. 5

2022

  1. Pharmacogene Variants Associated with Liver Transplant in a Twelve-Year Clinical Follow-Up

    Pharmaceutics, Vol. 14, Núm. 2

  2. Study of Oligonucleotides Access and Distribution in Human Peripheral Blood Mononuclear Cells

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

2021

  1. Foxp3 silencing with antisense oligonucleotide improves immunogenicity of an adjuvanted recombinant vaccine against sporothrix schenckii

    International Journal of Molecular Sciences, Vol. 22, Núm. 7

  2. Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

    Leukemia and Lymphoma, Vol. 62, Núm. 3, pp. 659-668

  3. Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia

    Pharmacogenetics and Genomics, Vol. 31, Núm. 6, pp. 133-139

  4. Integrated cgh/wes analyses advance understanding of aggressive neuroblastoma evolution: A case study

    Cells, Vol. 10, Núm. 10

  5. Mitochondrial dna replacement techniques to prevent human mitochondrial diseases

    International Journal of Molecular Sciences, Vol. 22, Núm. 2, pp. 1-23

  6. Multicompartmental lipopolyplex as vehicle for antigens and genes delivery in vaccine formulations

    Pharmaceutics, Vol. 13, Núm. 2, pp. 1-20

  7. Pharmacogenetics in neuroblastoma: What can already be clinically implemented and what is coming next?

    International Journal of Molecular Sciences, Vol. 22, Núm. 18

  8. Regulatory T cells and vaccine effectiveness in older adults. Challenges and prospects

    International immunopharmacology, Vol. 96, pp. 107761

2020

  1. Gold nanoparticle-assisted virus formation by means of the delivery of an oncolytic adenovirus genome

    Nanomaterials, Vol. 10, Núm. 6, pp. 1-16

  2. MTHFR and VDR polymorphisms improve the prognostic value of MYCN status on overall survival in neuroblastoma patients

    International Journal of Molecular Sciences, Vol. 21, Núm. 8

  3. Progress in the use of antisense oligonucleotides for vaccine improvement

    Biomolecules, Vol. 10, Núm. 2

2019

  1. CYP3A5∗3 and CYP2C8∗3 variants influence exposure and clinical outcomes of tacrolimus-based therapy

    Pharmacogenomics, Vol. 21, Núm. 1, pp. 7-21

  2. Colorectal cancer: Pharmacogenetics support for the correct drug prescription

    Pharmacogenomics, Vol. 20, Núm. 10, pp. 741-763

  3. Efficacy of interleukin 10 gene hydrofection in pig liver vascular isolated ‘in vivo’ by surgical procedure with interest in liver transplantation

    PLoS ONE, Vol. 14, Núm. 11